RACK1 Inhibitors for Treatment of Viral Infections
Connect with Industry
Categories: “”Viruses, Chronic & Infectious Diseases”
Reference #: 2015-035
OTC Contact: Ruchika Nijhara Ph.D., MBA (Directory Information | Send a Message)
Viruses require host factors to translate their transcripts and so targeting the host factor (s) offers an opportunity to develop broad spectrum anti-viral drugs. The receptor for Activated C Kinase I (RACK1) is one such host protein that some viruses use to translate their mRNAs using a viral mRNA secondary structure known as the Internal Ribosomal Entry Site (IRES). The present invention pertains to compounds and methods of treating infections from viruses containing a genome coding IRES by administering such RACK1 inhibitors that block IRES mediated translation of such viruses.
- Treating infections from viruses containing a genome having IRES including but not limited to hepatitis C (HCV), polio, Dengue, Cornaviruses, HIV and Herpes Simplex virus (HSV).
- The strategy of targeting the host factor, instead of the virus directly, potentially circumvents the damaging effect of resistance developed by viruses after the prolonged use of anti-viral drugs.
Stage of Development
Proof of concept demonstrated in vitro. The lead compound did not demonstrate any major toxicity linked to RACK1 inhibition.